Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000–2017

Kariniemi, Simo; Rantalaiho, Vappu; Virta, Lauri J.; Puolakka, Kari; Sokka‐Isler, Tuulikki; Elfving, Pia

doi:10.1177/0961203320967102

Cited by 9 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For each patient, one to three population controls matched according to age, sex, and place of residence at the ID were randomly selected from the Population Register Centre. The detailed identification method is explained in more detail in a previous study [ 19 ]. Any clinical data, or data regarding whether the patients fulfilled the classification criteria for SLE were not available.…”

Section: Methodsmentioning

confidence: 99%

Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case–control study

Elfving,

Kariniemi,

Kautiainen

et al. 2024

Rheumatol Int

Self Cite

View full text Add to dashboard Cite

Objectives The aim was to investigate, how pregnancies proceed in patients with systemic lupus erythematosus (SLE) compared to their individually matched population controls. Material and methods Adult incident SLE patients were identified from the register of new special reimbursement decisions for SLE drugs in 2000–2014. For each patient, 1–3 randomly selected controls from the Population Register Centre were matched. Data regarding pregnancies were obtained from the Finnish Medical Birth Register, Care Register and Register of Congenital Malformations until 2018. The study utilized data from the Drug Purchase Register and educational information from Statistic Finland. Results A total of 163 deliveries for 103 mothers with SLE and 580 deliveries for 371 population controls were identified. The duration of pregnancies in SLE women was significantly shorter compared to controls (38.9 versus 39.6 weeks). There were more urgent Caesarean Sections. (15% versus 9%) and need for care at neonatal intensive care unit (NICU) (21% versus 11%) among deliveries in SLE mothers. No statistical difference was observed between SLE and control groups in the occurrence of preeclampsia or major congenital malformations. Gestational age was 2.5 weeks shorter when the mother experienced pre-eclampsia. Hydroxychloroquine was purchased by 30% of SLE mothers during pregnancy. Conclusion The course of pregnancies in Finnish SLE patients seems to be quite moderate compared to controls, and no new safety issues were detected. The low utilization of hydroxychloroquine indicates that the benefits of the drug to pregnancy and disease course are not optimally recognized by specialists treating SLE mothers.

show abstract

Section: Methodsmentioning

confidence: 99%

Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case–control study

Elfving,

Kariniemi,

Kautiainen

et al. 2024

Rheumatol Int

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 Systemic lupus erythematosus is also related to a great number of comorbidities, such as cardiovascular diseases, infections and mood disorders. 2,3 Moreover, people with rheumatic diseases have a slightly higher risk for overall malignancy, and SLE is not an exception. 2,[4][5][6][7][8][9] Previous studies have shown that especially lymphomas and lung cancer are overrepresented among SLE patients.…”

Section: Introductionmentioning

confidence: 99%

Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival

Kariniemi

Rantalaiho

Virta

et al. 2022

Lupus

Self Cite

View full text Add to dashboard Cite

The objective of this study was to evaluate the incidence of malignancies among newly diagnosed systemic lupus erythematosus (SLE) patients compared to reference individuals. Another aim was to assess the survival of SLE patients with malignancy compared to references with malignancy. Finnish adult (>17 years) newly diagnosed SLE patients were identified by their drug reimbursement decisions made during 1.1.2000–31.12.2014 from the register of the Social Insurance Institution. For each case, three population controls were individually selected by age, sex and place of residence. Overall, 1006 SLE patients (women 84%), with a mean age of 45.5 years (SD 16 years) and 3005 population controls were linked to Finnish Cancer Registry, and the information about incident malignancies was retrieved from the day the special reimbursement decision for SLE medication was accepted (index day, ID) until 31.12.2018 or until death. The patients diagnosed with malignancy were followed up until 31.12.2019 considering survival. During the follow-up, 85 SLE patients (women 78%) and 192 controls (women 78%) had developed one or more malignancy after the ID. The incidence rate ratio for any malignancy was 1.41 (95% CI 1.08–1.85). The most common malignancy in SLE patients was non-Hodgkin lymphoma, with twelve cases. SLE patients with malignancy had a lower adjusted 15-year survival than controls with malignancy, 27.1% versus 52.4%, and the adjusted hazard ratio for death was 1.68 (95% CI 1.17–2.43). Our results confirm that SLE patients have a higher risk for overall malignancy. The results also suggest that SLE patients with malignancy have lower survival than their references with malignancy.

show abstract

“…Around the world, North America has the highest estimates of SLE incidence and prevalence (23.2/100,000 person/year and 241/100,000 people, respectively [3]. The patients with SLE have a significant burden as a result of the disease's multi-organ involvement and the therapeutic options available [4]. All-cause standard mortality rates in SLE patients increased 2.6 times [3].…”

Section: Introductionmentioning

confidence: 99%

The Mango’s Mistletoe Leaves Extract Ameliorates Lupus by Inhibiting the Anti-dsDNA Antibody Production, the Percentages of CD8+CD28− and CD4+CD28− T Cells

Handono¹,

Sunarti²,

Pratama³

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: In SLE patients, repeated antigen stimulations induce a progressive reduction in CD28 expression on the surface of T cells and the chronic inflammation condition. Mango’s mistletoe is a parasitic plant that has anti-inflammation, antiproliferation, and immunomodulatory activities. AIM: This study aimed to investigate the effect of mango’s mistletoe leaves extract (MLE) in inhibiting anti-dsDNA antibodies and ameliorating the percentages of CD8+CD28− and CD4+CD28− T cells in a pristane-induced lupus mice model. METHODS: Lupus induction was undertaken by an injection of pristane 0.5 ml intraperitoneally in 6–8-week-old female balb/c mice. Mice with lupus signs were grouped randomly into the treatment groups which received MLE at doses of 150, 300, and 600 mg/kgbw/d for 28 days, respectively, and the positive control group without MLE. On day 29, anti-dsDNA antibody levels were analyzed using an ELISA. One of the immunosenescence markers (CD28− T cells) was investigated using a flow cytometer. ANOVA test was used for statistical analysis. RESULTS: The mango’s mistletoe leaves extract (MLE) significantly decreased the number of anti-dsDNA antibodies (*p < 0.05), the percentages of CD8+CD28− T cells (*p < 0.05) and CD4+CD28− T cells (*p < 0.05). CONCLUSION: We resume that the mango’s mistletoe leaves can ameliorate lupus by inhibiting anti-dsDNA antibody production and the percentages of CD8+CD28− and CD4+CD28− T cells.

show abstract

Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000–2017

Cited by 9 publications

References 42 publications

Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case–control study

Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case–control study

Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival

The Mango’s Mistletoe Leaves Extract Ameliorates Lupus by Inhibiting the Anti-dsDNA Antibody Production, the Percentages of CD8+CD28− and CD4+CD28− T Cells

Contact Info

Product

Resources

About